The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Rezolute , Inc. (NASDAQ:RZLT), a clinical-stage biopharmaceutical company, is making significant strides in the development of its lead drug candidate, ersodetug, for the treatment of congenital ...
A magnifying glass. It indicates, "Click to perform a search". A magnifying glass. It indicates, "Click to perform a search". The word "Markets Insider". REDWOOD CITY, Calif., Jan. 27, 2020 (GLOBE ...
On the 5th (local time), HANDOK's affiliate Rezolute announced on the 7th that its hypoglycemia treatment candidate RZ358 (Ersodetug), related to tumor-mediated hyperinsulinemia, received Breakthrough ...
REDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by all ...
REDWOOD CITY, Calif., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for ...
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt ...
REDWOOD CITY, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OTCQB:RZLT) today announced top-line results from its Phase 1 trial of AB101, an ultra-long acting ...
Rezolute Inc.’s phase III Sunrize study of its only candidate, ersodetug, a fully human monoclonal antibody that binds to allosteric site on insulin receptors, missed its primary and secondary ...
Rezolute Inc. (NASDAQ:RZLT) is one of the top long-term biotechnology stocks to buy. Wedbush analyst Yun Zhong reaffirmed a Buy rating on Rezolute Inc. (NASDAQ:RZLT) stock on October 23, citing strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results